Arcadia Biosciences, Inc.
NASDAQ Capital MarketTotal Valuation
Arcadia Biosciences, Inc. carries a market capitalization of 731,262.00, placing it among publicly traded companies globally. Its enterprise value stands at -2.70M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 731,262.00 |
| Enterprise Value | -2.70M |
Share Statistics
Arcadia Biosciences, Inc. currently has 2.18M shares outstanding.
| Shares Outstanding | 2.18M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 2.34.
| PE Ratio | N/A |
| PS Ratio | 0.31 |
| PB Ratio | 2.34 |
| P/TBV Ratio | 2.49 |
| P/FCF Ratio | -0.58 |
| P/OCF Ratio | -0.58 |
Financial Position
Arcadia Biosciences, Inc. maintains a current ratio of 3.49, meaning it holds 3.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.49 |
| Quick Ratio | 2.88 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -430.93 |
| Return on Assets (ROA) | -162.72 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -63.58 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.57 |
Stock Price Statistics
Arcadia Biosciences, Inc.'s stock has declined approximately -85.59146% over the past 52 weeks. The 50-day moving average sits at 0.61, while the 200-day moving average is 1.58.
| Beta (5Y) | N/A |
| 52-Week Price Change | -85.59146% |
| 50-Day Moving Average | 0.61 |
| 200-Day Moving Average | 1.58 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Arcadia Biosciences, Inc. generated 4.75M in revenue and converted that into -11.13M in net income, yielding earnings per share of -5.18. EBITDA reached -4.05M, while operating income came in at -4.06M.
| Revenue | 4.75M |
| Gross Profit | 1.64M |
| Operating Income | -4.06M |
| Pretax Income | -11.12M |
| Net Income | -11.13M |
| EBITDA | -4.05M |
| EBIT | -4.06M |
| Earnings Per Share (EPS) | -5.18 |
Balance Sheet
Total book value stands at 633,000.00, with working capital of 4.09M providing operational flexibility.
| Cash & Cash Equivalents | 4.18M |
| Total Debt | N/A |
| Net Debt | -4.18M |
| Equity (Book Value) | 633,000.00 |
| Book Value Per Share | 0.29 |
| Working Capital | 4.09M |
Cash Flow
Arcadia Biosciences, Inc. produced -2.54M in operating cash flow over the past twelve months.
| Operating Cash Flow | -2.54M |
| Capital Expenditures | N/A |
| Free Cash Flow | -2.54M |
| FCF Per Share | -1.18 |
Margins
Arcadia Biosciences, Inc. operates with a gross margin of 34.58, reflecting its pricing power and cost economics. The operating margin of -85.52 and net profit margin of -234.53 provide insight into operational efficiency.
| Gross Margin | 34.58 |
| Operating Margin | -85.52 |
| Pretax Margin | -234.37 |
| Profit Margin | -234.53 |
| EBITDA Margin | -85.27 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -360.29 |
| FCF Yield | -173.76 |
Stock Splits
Arcadia Biosciences, Inc.'s most recent stock split took place on March 1, 2023 with a 40:1 split ratio.
| Last Split Date | 3/1/2023 |
| Split Ratio | 40:1 |
Scores
Arcadia Biosciences, Inc. posts an Altman Z-Score of -70.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -70.27 |